权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Molecular assemblies as immunomodulators

作为免疫调节剂的分子组装体

基本信息

批准号：
8309672
负责人：
Gregory Hudalla
金额：
$ 5.22万
依托单位：
UNIVERSITY OF CHICAGO
依托单位国家：
美国
项目类别：
财政年份：
2011
资助国家：
美国
起止时间：
2011-08-01 至 2014-07-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8309672
关键词：
Address Adjuvant Antibodies Antibody Formation Antigens B-Lymphocyte Epitopes Binding Biocompatible Materials Chemicals Chimeric Proteins Development Disaccharides Engineering Enzymes Epitopes Future Galactose Binding Lectin Galectin 1 Green Fluorescent Proteins Haplotypes Immobilization Immune Immune response Immunomodulators Immunotherapy Implant Life Ligands Maternal-Fetal Exchange Mediating Modeling Mus N-acetyllactosamine Outcome Peptides Polymers Process Proteins Reaction Regenerative Medicine Research Research Design Role Solvents Sulfhydryl Compounds System T-Lymphocyte Testing Tissue Engineering Tissues Vaccine Adjuvant Vaccine Antigen Vaccines Work base biomaterial development clinical application clinically relevant covalent bond cutinase design fetal immunogenic immunogenicity implantation improved in vivo methicillin resistant Staphylococcus aureus molecular assembly/self assembly mouse model pathogen patient population phosphonate polyclonal antibody polysaccharide peptide response tissue regeneration tumor

项目摘要

DESCRIPTION (provided by applicant): Biomolecular assemblies that modulate host immune responses have widespread potential in immunotherapy and tissue engineering applications. For example, self-assembled peptides that boost host immune responses may provide chemically well-defined vaccine adjuvants with precise mechanisms of action. On the other hand, self-assembled peptides that diminish host immune responses may improve the efficacy of tissue engineering therapies by alleviating the potential for tissue or implant rejection. This project is guided by the hypothesis that self-assembled peptides decorated with foreign proteins will elicit robust immune responses, while self-assembled peptides engineered to mimic mechanisms that inhibit immune responses within natural systems will diminish the immunogenicity of these biomaterials. This project is based on the well-defined immune response to peptide antigen- decorated self-assembled peptide biomaterials, which are non-immunogenic in the absence of antigen. Aim 1 will engineer immunogenic self-assembled peptide biomaterials presenting protein antigens. The model protein antigen green fluorescent protein (GFP) will be immobilized on a self-assembled peptide biomaterial through formation of a covalent bond between an enzyme fused to GFP and a ligand presented by the material. The immunogenicity of GFP-modified self-assembled peptide biomaterials will then be characterized in vivo in a mouse model. These studies are designed to provide proof-of-principle that self- assembled peptide biomaterials decorated with a protein antigen elicit robust and long-lived immune responses. The outcomes of this aim will provide the basis for developing biomaterial-based vaccines against clinically-relevant pathogens, such as methicillin-resistant staphylococcus aureus. Aim 2 will engineer self-assembled peptide biomaterials that diminish anti-material immune responses by mimicking native immune privilege mechanisms. In this aim, the GFP-modified self- assembled peptide biomaterials developed in S.A.1 will be further modified with a disaccharide that non- covalently binds to the protein galectin-1. The choice of galectin-1 as a negative modulator of immune response is based on the wel-established role of galectins in tumor immune privilege and fetal-maternal tolerance. Self-assembled peptide biomaterials decorated with GFP and a galectin-binding disaccharide will then be injected into mice in the presence or absence of soluble galectin-1. The immune response to these materials will be analyzed using the same models and approaches as in S.A.1. These studies are designed to provide proof-of-principle that biomaterials engineered to mimic native mechanisms of immune privilege diminish the immune response to the material. The outcomes of this aim will provide the basis for developing biomaterials that diminish host immune responses to limit rejection of tissues or implants for tissue engineering and regenerative medicine therapies.

描述（由申请人提供）：调节宿主免疫反应的生物分子组件在免疫治疗和组织工程应用中具有广泛的潜力。例如，促进宿主免疫反应的自组装肽可能提供化学上定义明确的疫苗佐剂，具有精确的作用机制。另一方面，减少宿主免疫反应的自组装肽可能通过减轻组织或植入物排斥的可能性来提高组织工程治疗的疗效。该项目基于这样的假设：用外源蛋白修饰的自组装肽将引发强大的免疫反应，而在自然系统中模拟抑制免疫反应机制的自组装肽将降低这些生物材料的免疫原性。这个项目是基于对肽抗原修饰的自组装肽生物材料的明确免疫反应，这种材料在没有抗原的情况下是非免疫原性的。目的1将设计免疫原性自组装肽生物材料，呈现蛋白质抗原。模型蛋白抗原绿色荧光蛋白（GFP）将通过与GFP融合的酶与材料呈现的配体之间形成共价键固定在自组装的肽生物材料上。gfp修饰的自组装肽生物材料的免疫原性将在小鼠模型中进行体内表征。这些研究旨在提供原理证明，用蛋白质抗原修饰的自组装肽生物材料可引起强大而持久的免疫反应。这一目标的结果将为开发针对临床相关病原体（如耐甲氧西林金黄色葡萄球菌）的基于生物材料的疫苗提供基础。目标2将设计自组装肽生物材料，通过模仿天然免疫特权机制来减少抗物质免疫反应。为此，在S.A.1开发的gfp修饰的自组装肽生物材料将进一步用非共价结合半乳糖凝集素-1蛋白的双糖修饰。选择半乳糖凝集素-1作为免疫反应的负调节因子是基于半乳糖凝集素在肿瘤免疫特权和胎儿-母体耐受中的良好作用。用GFP和半乳糖凝集素结合双糖修饰的自组装肽生物材料将在存在或不存在可溶性半乳糖凝集素-1的情况下注射到小鼠体内。对这些材料的免疫反应将使用与S.A.1相同的模型和方法进行分析。这些研究的目的是提供原理证明，生物材料被设计成模仿免疫特权的天然机制，减少对材料的免疫反应。这一目标的结果将为开发减少宿主免疫反应的生物材料提供基础，以限制组织工程和再生医学治疗中组织或植入物的排斥反应。